Dupilumab in children aged 2 to <6 years with uncontrolled asthma or recurrent severe asthmatic wheeze

Randomised, double-blind trial in asthma comparing Dupilumab (double-blind period) with Placebo (2 arms). Primary endpoints: Annualized rate of severe asthma exacerbations during the 52-week treatment period and Incidence of treatment-emergent adverse events, serious adverse events, adverse events of special interest, and adverse events leading to permanent treatment discontinuation. Started Jun 2025; status: active, not recruiting.